Physician profile
Ratinder Jit Kaur
NPI 1154653228
$2,253.39
in general payments reported to CMS, 2019-2025
25 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.95 · 2020: $288 · 2021: $609 · 2022: $402 · 2023: $396 · 2024: $307 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $336.94 | 2020-2024 | |
| Janssen Biotech, INC. | $281.21 | 2020-2022 | |
| Amgen INC. | $266.60 | 2019-2023 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $239.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.07 | 2020-2025 | Orencia |
| Organon LLC | $124.35 | 2021-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $124.00 | 2020-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.85 | 2021-2023 | Ofev |
| Genentech USA, INC. | $74.68 | 2020-2022 | |
| Ucb, INC. | $59.68 | 2020-2024 | Bimzelx |
| Pfizer INC. | $53.17 | 2019-2021 | |
| Boston Scientific Corporation | $50.01 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $49.32 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $48.66 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $38.47 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $32.90 | 2025 | |
| Sobi, INC | $22.18 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $19.78 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.45 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.17 | 2023 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $16.83 | 2021 | |
| Radius Health, INC. | $16.35 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.29 | 2025 | Purified Cortrophin Gel |
| Celgene Corporation | $13.06 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.